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E-mail address: hjono@fc.kuh.kumamoto-u.ac.jp (HAlthough transthyretin (TTR) is expressed in pancreatic alpha (glucagon) cells in the islets of Langer-
hans, the function of TTR in pancreatic alpha cells remains unknown. In this study, by using TTR
knockout (TTR KO) mice, we determined the novel role of TTR in glucose homeostasis. We demon-
strated that TTR KO mice evidenced impaired recovery of blood glucose and glucagon levels. Lack of
TTR induced signiﬁcantly lower levels of glucagon in the islets of Langerhans. These results suggest
that TTR expressed in pancreatic alpha cells may play important roles in glucose homeostasis via
regulating the expression of glucagon.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Glucagon, a peptide hormone of 29 amino acids, is synthesized
in and secreted from pancreatic alpha cells of the islets of Langer-
hans in response to mixed nutrient meals, administration of oral or
intravenous (i.v.) amino acids, activation of the autonomic nervous
system, and hypoglycemia [1,2]. The main action of glucagon is to
raise blood glucose levels in response to hypoglycemia by increas-
ing hepatic glycogenolysis and gluconeogenesis [3]. The circulating
half-life of immunoreactive glucagon in humans is estimated to be
between 5 and 6 min [4]. It is well known that the balance between
insulin and glucagon controls glucose homeostasis [5]. Thus, the
primary role of glucagon is correcting hypoglycemia caused by
malnutrition, fasting, and treatment of diabetes to achieve normo-
glycemia [6–9]. Insulin treatment in diabetes, especially type 1
diabetes, greatly increases the risk of hypoglycemia, with effectschemical Societies. Published by E
-PCR; TTR, transthyretin; TTR
in tolerance test
iagnostic Medicine, Graduate
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. Jono).on a number of organs including brain, and causes critical systemic
symptoms such as hypoglycemic coma [10–12]. In addition, an
absent glucagon response plays a prominent role in a failure to cor-
rect hypoglycemia induced by insulin and may exacerbate critical
systemic symptoms [8]. Therefore, tight control of glucagon secre-
tion has signiﬁcant implications for stable glucose homeostasis.
Transthyretin (TTR) is a functional plasma protein, which forms
a tetramer composed of four identical subunits, and serves as a
transport protein for thyroxine in association with retinol-binding
protein [13]. TTR is synthesized predominantly by the liver, which
is therefore the main source of TTR in plasma [14,15]. It is well-
documented that plasma TTR levels are reduced in inﬂammatory
conditions and in malnutrition caused by surgery or chronic dis-
eases [16–19]. However, TTR is expressed in considerable amounts
in the choroid plexus, retinal pigment epithelium, pancreatic alpha
and beta cells, although the function of TTR synthesized by these
particular cells is largely unknown [20–24]. Certain studies re-
ported a signiﬁcantly lower plasma TTR level in diabetic patients
than in non-diabetic subjects [25,26]. Moreover, in islet beta cells
of the pancreas, TTR promoted insulin stimulus-secretion coupling
and protected against beta cell apoptosis in type 1 diabetes [27]. In
addition, TTR has been shown to be normally expressed inlsevier B.V. All rights reserved.
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over, it has also been shown that TTR co-localized with glucagon
exactly in pancreatic alpha cells, suggesting that TTR synthesized
by pancreatic alpha cells may be involved in glucose homeostasis
[24]. However, the biological signiﬁcances of TTR expressed in pan-
creatic alpha cells remain unknown.
In view of the evidences provided in previous reports, we
hypothesized that TTR may play important roles in glucose homeo-
stasis. In this study, we focused on TTR that is synthesized by pan-
creatic alpha cells, and we evaluated the possible role of TTR in
expression and plasma levels of glucagon during glucose
ﬂuctuations.
2. Materials and methods
2.1. Animals
Wild-type (WT) and TTR knockout (TTR KO) mice in the C57BL/
6 J background [28], were used in this study. Mice were adult
males, each 8–10 weeks old and each weighing 20–25 g. The ani-
mals were maintained in a pathogen-free environment at the Cen-
ter for Animal Resources and Development, Kumamoto University.
2.2. Insulin tolerance test (ITT)
In the ITT, performed after a 3-h fast, human regular insulin
(1 IU/kg) was administered intraperitoneally (i.p.) to mice, and
the blood glucose level was measured by using an Accu-Chek In-
form Blood Glucose Monitoring System (Roche Diagnostics, India-
napolis, IN).
2.3. Fasting conditions and collection of samples
Plasma samples of mice for ELISA were collected at 0, 6, 12, and
24 h after fast. Samples of pancreas and liver for (qRT-PCR) were
sharply excised, and then immediately frozen in liquid nitrogen.
2.4. Cells and cell culture
The cell lines PANC-1 (human pancreas epithelioid carcinoma
cells), alpha TC1 clone 6 (mouse pancreatic alpha cells), and HepG2
(human hepatocellular carcinoma cells) were obtained from ATCC
(Manassas, VA) and were cultured in DMEM (Invitrogen, Grand Is-
land, NY) supplemented with 10% FBS. All cells were grown in 5%
CO2 at 37 C.
2.5. RNA isolation and qRT-PCR
Total RNA was isolated from each tissue specimen and treated
cells by using TRIzol (Invitrogen, Carlsbad, CA), according to the
manufacturer’s protocol. Total RNA (0.5 lg) was reverse-
transcribed to cDNA by using the ExScript RT reagent (Takara Bio
Inc., Shiga, Japan) according to the manufacturer’s instructions.
Each PCR reaction was done with 2 ll of cDNA and 0.2 lM of each
primer in a LightCycler System with SYBR Premix Ex Taq (Takara
Bio Inc.). Agarose gel electrophoresis was also performed as
previously described. The following primers were used: mouse
glucagon: forward, 5-TGAATTTGAGAGGCATGCTG-3; reverse, 5-
GGTTTGAATCAGCCAGTTGA-3; mouse TTR: forward, 5-CATGAAT
TCGCGGATGTG-3; reverse, 5-GATGGTGTAGTGGCGATGG-3; mouse
b-actin: forward, 5-TGACAGGATGCAGAAGGAGA-3; reverse, 5-GC
TGGAAGGTGGACAGTGAG-3; human TTR: forward, 5-CATTCTTG
GCAGGATGGCTTC-3; reverse, 5-CTCCCAGGTGTCATCAGCAG-3;
and human glyceraldehyde-3-phosphate dehydrogenase (GAPDH):
forward, 5-GCACCGTCAAGGCTGAGAAC-3; reverse, 5-ATGGTGGTG
AAGACGCCAGT-3.2.6. Transfection and fasting in vitro
Cells were cultured in 12 well culture plates (Becton, Dickinson,
Franklin Lakes, NJ) at a density of 2  105 cells per well, at 37 C in
a humidiﬁed atmosphere of 5% CO2 in air for 48 h. Conﬂuent alpha
TC1 clone 6 cells were transfected with two different kinds of siR-
NA against murine TTR, and PANC-1 cells were transfected with
human TTR plasmid by using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol. After incubation for 24
or 48 h in serum-free medium, total RNA and protein were
isolated. Alpha TC1 clone 6 cells or PANC-1 cells transiently
transfected with control siRNA or control vector were used as con-
trols. Chemical siRNA sequences for TTR siRNA1 were as follows:
TTR siRNA1 sense strand 50-CAGUGUUCUUGCUCUAUAATT-30,
TTR siRNA1 antisense strand 50-UUAUAGAGCAAGAACACUGTT-30
(Sigma–Aldrich, Tokyo, Japan). For evaluation of the effect of
fasting on cells, after cells were incubated in serum-free high-
glucose or low-glucose DMEM for 72 h, and thereafter total RNA
was isolated.
2.7. Protein extraction form pancreas and pancreatic islets
Protein in the total pancreas and isolated pancreatic islets from
mice was obtained by using acid ethanol (15% 1 M HCl, 75% etha-
nol, 10% H2O).
2.8. Isolation of pancreatic islets
Mouse pancreatic islets were isolated by means of collagenase
digestion. Mice were anesthetized by i.p. with sodium thiopental.
Collagenase (collagenase type S-1, 0.6 mg/ml; Nitta Gelatin Inc.,
Osaka, Japan) was dissolved in Hanks’ Balanced Salt Solutions
(Sigma–Aldrich) with 800 KIU/ml aprotinin (Wako, Osaka, Japan).
The collagenase solution was injected into the common bile duct.
Pancreas were dissected and incubated in the collagenase
solution at 37 C for 20 min with shaking. These samples were
then mixed with ice-cold isotonic sucrose buffer and were chilled
on ice for 20 min. Clariﬁed islets were collected for use in
experiments.
2.9. Analysis of glucagon secretion
After being incubated in DMEM for 24 h, 5 groups, for each
group contained 15 islets, were incubated for 1 h in Ca2+-
containing HEPES-added Krebs–Ringer bicarbonate buffer (HKRB)
with 2.2 mM glucose in 5% CO2 at 37 C, followed by test
incubation for 1 h in HKRB with 2.2 or 22 mM glucose.
2.10. Immunohistochemical staining
Parafﬁn-embedded 4-lm-thick sections were prepared and
deparafﬁnized in xylene and rehydrated in graded alcohols. Slides
were treated with periodic acid for 10 min at room temperature,
after which they were incubated in 5% normal serum for 1 h at
room temperature in a moist chamber. For immunohistochemical
staining of glucagon, a polyclonal rabbit anti-glucagon antibody
(Cell Signaling Technology, Danvers, MA), diluted 1:100 in dilu-
tion buffer, served as the primary antibody. Rabbit anti-mouse
TTR antiserum, diluted 1:50 in dilution buffer, served as the
primary antibody for mouse TTR. The secondary antibody was
an HRP-conjugated goat anti-rabbit immunoglobulin antibody
(Dako, Glostrup, Denmark) diluted 1:100 in buffer. The dilution
buffer was 0.5% Bovine serum albumin (BSA). Reactivity was
visualized via the DAB Liquid System (Dako), according to the
manufacturer’s instructions. Sections were counterstained with
hematoxylin.
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The glucagon concentration in plasma, extracts of total pancreas
and islets from mice, and cell lines was measured by using the Rat
Glucagon ELISA Kit (Wako), according to the manufacturer’s
instructions for undiluted plasma samples, 1000 times dilution of
extracts of pancreas and islets, 500 times dilution of cell superna-
tants, and 50 times dilution of cell lysates.
2.12. Statistics
Data were expressed as means ± S.D. and ±S.E.M., according to
the previous study [29]. Controls and treated groups were com-
pared by using Student’s t test. The accepted level of signiﬁcance
was P < 0.05.
3. Results
3.1. Change in blood glucose levels in WT and TTR KO mice during the
ITT
RT-PCR conﬁrmed expression of TTR mRNA in the pancreas of
mice (Fig. 1A). In sections of pancreatic tissues, TTR was expressed
in all islets fromWTmice, with cells showing a preferential periph-
eral distribution, but islets from TTR KO mice evidenced no TTR
expression (Fig. 1A). ITT showed that the blood glucose level in
WT mice started to recover at 30 min after the insulin injection
(Fig. 1B). However, those in TTR KO mice decreased sharply by
60 min after the injection compared with the baseline of the blood
glucose level. Furthermore, TTR KO mice had continuously sup-
pressed blood glucose levels compared with WT mice at 60, 90,
120, and 180 min after the insulin injection (Fig. 1B). We assumed
that the impaired plasma glucagon levels caused the sharp de-
crease of the blood glucose levels in the ITT.
3.2. Plasma glucagon levels in WT and TTR KO mice in the ITT and
during fasting
We next investigated plasma glucagon levels in WT and TTR KO
mice. As Fig. 2A shows, although WT mice showed higher plasmaFig. 1. TTR expression in pancreatic tissues of mice and changes in blood glucose levels in
mice (top panel); TTR expression in islets from WT mice, with cells showing a preferen
(bottom panel). Scale bars = 100 lm. (B) Mice received human regular insulin (1 IU/kg i
(mean ± S.E.M.). n = 6. ⁄P < 0.05.glucagon levels after the insulin injection, TTR KO mice showed a
much smaller increase in plasma glucagon levels in a time-depen-
dentmanner after the injection. In addition, in sections of pancreatic
tissues fromWT and TTR KO mice at 20 min after the insulin injec-
tion, almost all of the islets fromWTmice demonstrated strong glu-
cagon immunoreactivity, but islets from TTR KO mice showed only
weak immunoreactivity (Fig. 2B). Furthermore, we compared plas-
ma glucagon levels between WT and TTR KO mice during chronic
glucoseﬂuctuations induced by fasting. As seen in Fig. 2C, consistent
with the results of the ITT, TTR KO mice showed signiﬁcantly lower
plasma glucagon level by fasting. In contrast to the glucagon levels,
no signiﬁcant difference of plasma insulin levels between WT and
TTR KO mice was observed (Fig. S1).
3.3. Glucagon content in pancreatic islets from WT and TTR KO mice
We next determined the glucagon content in pancreatic islets
fromWT and TTR KO mice. Under normal conditions, pancreatic is-
lets fromWTmice demonstrated a strong positive immunoreactiv-
ity for glucagon, with a preferential distribution in the periphery
(Fig. 3A). Pancreatic islets from TTR KO mice, however, showed a
much weaker positive reaction (Fig. 3A). The quantitative analysis
showed that in TTR KO mice, the glucagon content in the total pan-
creas was signiﬁcantly lower than that for WT mice, i.e., about 10%
of the glucagon content of WT mice (Fig. 3B). To conﬁrm these re-
sults, pure pancreatic islets were isolated and analyzed. As seen in
Fig. 3C, similar to the results for the total pancreas, the glucagon
content in islets isolated from TTR KO mice was about 50% of that
in from WT mice.
3.4. Glucagon secretion from pancreatic islets isolated from TTR KO
mice
To conﬁrm the results obtained from in vivo experiments,
glucagon secretion from pure pancreatic islets-isolated from WT
and TTR KO mice were analyzed. Transfer from high-glucose
condition to low-glucose condition has been shown to induce
glucagon secretion from pancreatic islets. In our study, performed
under similar conditions, pancreatic islets from WT mice showedWT and TTR KOmice during the ITT. (A) Expression of TTR mRNA in the pancreas of
tial peripheral distribution (middle panel), but no TTR expression in TTR KO mice
.p.), and the serum glucose level was monitored at 0, 30, 60, 90, 120, and 180 min
Fig. 2. Plasma glucagon levels in WT and TTR KO mice in the ITT and during fasting. (A) Mice underwent the ITT, and plasma glucagon was measured at 0, 10, 20, and 30 min
by using ELISA (mean ± S.E.M.). n = 10. (B) Examples of pancreatic islets from mice after the ITT. At 20 min after ITT, immunohistochemistry revealed high-intensity glucagon
staining in pancreatic islets from WT mice (left) and low-intensity glucagon staining in pancreatic islets from TTR KO mice (right). Scale bars = 100 lm. (C) Mice were fasted
for 24 h, and plasma glucagon was measured by ELISA at 0, 6, 12, and 24 h (mean ± S.E.M.). n = 11. ⁄P < 0.05.
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the high-glucose condition. In addition, islets from TTR KO mice
had glucagon levels similar to those of WTmice in the high-glucose
condition. However, no increase in glucagon level was observed in
the islets from TTR KO mice in response to the low-glucose
condition, in contrast to WT mice. The glucagon levels in the islets
from TTR KO mice were signiﬁcantly lower than those from WT
mice under low-glucose conditions (Fig. 4A). We also evaluated
the glucagon contents remaining in pancreatic islets after glucagon
secretion. Pancreatic islets from TTR KO mice showed a signiﬁ-
cantly lower level of glucagon than islets fromWTmice-only about
40% of the WT level (Fig. 4B). Because the TTR KO islets showed the
lower glucagon content, we assumed that the content of glucagon
was impacted by the decrease of glucagon expression.
3.5. Changes in glucagon expression as related to TTR expression
We next determined glucagon mRNA levels after 12 h of fasting.
Expression of glucagon mRNA in the total pancreas from TTR KO
mice was signiﬁcantly lower than that from WT mice (Fig. 5A).While, no obvious alteration was seen in insulin mRNA expression
(Fig. S2). In addition, downregulation of TTR expression by two dif-
ferent sequences of TTR siRNA led to a signiﬁcant reduction in glu-
cagon expression in alpha TC1 clone 6 cells at both mRNA
andprotein levels (Fig. 5B, Figs. S3 and S4). In contrast, overexpres-
sion of WT-TTR by using the TTR plasmid signiﬁcantly increased
glucagon mRNA expression in PANC-1 cells (Fig. 5C).
3.6. Starvation-induced changes in pancreatic TTR expression
Previous reports demonstrated that TTR levels decreased during
progressive malnutrition and that this effect was linked to expres-
sion of TTR in the liver, the main organ of production of TTR circu-
lating in the blood [17]. In our study, as expected, expression of
TTR in the liver from WT mice signiﬁcantly decreased. In contrast,
expression of TTR in the total pancreas fromWTmice markedly in-
creased, about 2.5 times, during starvation induced by fasting for
24 h (Fig. 6a and b). Similar to the results obtained from in vivo
experiments, HepG2 cells, a liver cell line, showed a marked reduc-
tion in TTR expression after incubation under low-glucose
Fig. 3. Glucagon content in pancreatic islets from WT and TTR KO mice. (A) An example of high-intensity glucagon staining in pancreatic islets from WT mice (top) and low-
intensity glucagon staining in pancreatic islets from TTR KO mice (bottom). Scale bars = 100 lm. (B) Glucagon content in the total pancreas from WT and TTR KO mice as
measured by ELISA (mean ± S.D.). n = 6. (C) Glucagon content in isolated pancreatic islets from WT and TTR KO mice, as measured by ELISA (mean ± S.D.). n = 3. ⁄P < 0.05.
Fig. 4. Glucagon secretion from pancreatic islets from WT and TTR KO mice. (A) Pancreatic islets isolated from WT and TTR KO mice were incubated under high- (22 mM) or
low- (2.2 mM) glucose condition. Glucagon levels were assessed by ELISA (mean ± S.E.M.). n = 5. ⁄P < 0.05. n.s., not signiﬁcant. (B) Remaining glucagon contents in isolated
pancreatic islets from WT and TTR KO mice after glucagon secretion after incubation in low-glucose condition, as measured by ELISA (mean ± S.E.M.). n = 5. P < 0.01.
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signiﬁcantly increased glucagon mRNA expression after incubation
in glucose-poor medium for 48 h (Fig. 6c and d).
4. Discussion
A previous report suggests that, on the basis of electron micro-
scopic evidence, TTR in pancreatic islets is mainly expressed in
pancreatic alpha cells and is stored in secretory vesicles [24]. In
the present study, we demonstrated that TTR KO mice, compared
with WT mice, evidenced impaired blood glucose recovery and
plasma glucagon levels during both acute and chronic glucose ﬂuc-
tuations. These results were conﬁrmed by using isolated pancreaticislets from WT and TTR KO mice. These interesting phenomena
suggest that TTR plays important roles in glucose homeostasis dur-
ing glucose ﬂuctuations, especially periods of low blood glucose
levels, by regulating the amount of glucagon secreted.
One interesting ﬁnding of this study is that the lack of TTR
reduced the plasma glucagon level during both acute and chronic
glucose ﬂuctuations. Glucagon and insulin constitute part of a
feedback system that keeps blood glucose levels stable. The
reduced glucagon level destroys the balance between insulin and
glucagon, and affects the stability of blood glucose levels. These ef-
fects may be ampliﬁed by injections of insulin used to treat insulin-
dependent diabetes, or by long periods of malnutrition. The pan-
creas releases glucagon when blood glucose levels fall too low,
Fig. 5. Effects of TTR on glucagon expression. (A) Mice were fasted for 12 h, and glucagon mRNA expression was measured by means of qRT-PCR (mean ± S.D.). n = 14. (B)
effect of blocking TTR signaling on glucagon mRNA expression in alpha TC1 clone 6 cells. Blocking was achieved by using TTR siRNA (100 nM) (mean ± S.D.). n = 3. (C) Effect of
TTR overexpression on glucagon mRNA expression in PANC-1 cells. Overexpression was achieved by using TTR plasmid (0.3 lg) (mean ± S.D.). n = 3. ⁄P < 0.05; P < 0.01.
Fig. 6. Effects of starvation on TTR expression in pancreas and liver. WT mice were fasted for 24 h, and TTR mRNA expression in pancreas (A) and liver (B) was measured by
means of qRT-PCR (mean ± S.D.). (C) and (D) alpha TC1 clone 6 (C) or HepG2 (D) cells were incubated under high- or low-glucose condition for 72 h. TTR mRNA expression was
measured by means of qRT-PCR (mean ± S.D.). n = 3. ⁄P < 0.05; P < 0.01.
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into glucose, which is released into the bloodstream. Low plasma
glucagon levels cause a failure in the relief of acute or chronic se-
vere hypoglycemia, which affects many important organs and ma-
jor physiological functions [6]. Especially, because neurons cannot
use other energy sources such as fatty acids to any great degree,
brain depends absolutely on glucose as a fuel [30]. Thus, rapid re-
sponse and dynamic glucagon secretion when blood glucose levelsare low is extremely important for maintenance of glucose homeo-
stasis. Our data suggest that TTR performs a novel function and
plays important roles in stabilizing blood glucose levels via control
of glucagon. It should be noted that, despite the well-known fact
that glucagon concentration is regulated by insulin concentration,
no obvious difference in plasma insulin levels was observed be-
tween WT and TTR KO mice (Fig. S1). These data suggest that
TTR in pancreatic alpha cells played an important role to increase
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tional TTR KO mouse which lack TTR only in pancreas may help
conﬁrming these ﬁndings. Our future studies will focus on more
precise determination of the roles of TTR in glucose homeostasis.
In the present study, we found that TTR KO mice showed a sig-
niﬁcantly lower glucagon content compared withWTmice, and we
found a similar phenomenon in the in vitro studies using pancre-
atic islets. It should be noticed that the similar numbers of pancre-
atic islets in whole pancreas of WT and TTR KOmice were observed
by microscope (average number of WT: 32 ± 6/ﬁeld; TTR KO:
28 ± 4/ﬁeld). Moreover, we found that glucagon mRNA expression
in pancreatic cell lines had a high positive association with the le-
vel of TTR expression. These results suggest that the lack of TTR im-
paired the accumulation or storage of glucagon in pancreatic alpha
cells, and we considered that the reduced contents of glucagon
could be caused by the decrease of mRNA levels. As shown in Figs. 1
and 2, by ITT, plasma glucagon levels 20 min post-injection were
lower in TTR KO than WT, and signiﬁcant differences were noted
from 60 min in blood glucose level. These results suggest that be-
cause pancreatic alpha cells rapidly secrete abundant glucagon in
response to hypoglycemia, and since the half-life of glucagon is rel-
atively short, 5–6 min [4], the lack of TTR may reduce the level of
glucagon mRNA, which in turn leads to the deﬁciency of plasma
glucagon levels for insulin antagonistic activity. Although the role
of TTR in glycogenolysis in liver has yet to be determined, TTR
may serve as one of the enhancers of glucagon expression after
acute secretion of glucagon in pancreatic alpha cells. Also, we pre-
viously reported that glucose metabolism is impaired in familial
amyloidotic polyneuropathy, which is caused by mutated TTR, in
which amyloid deposition commonly occurs in the pancreas [31].
Previous reports demonstrated that glucagon gene expression is
tightly controlled by various transcription factors, such as Pax6,
Foxa1, Foxa2, and MafB/cMaf [2,32,33]. Of these transcription fac-
tors, Foxa2 (also called hepatic nuclear factor-3) is known to be
essential for strong expression of TTR gene in the liver [34,35]. It
should be noted that Pax6 mRNA expression was signiﬁcantly re-
duced by TTR knockdown with siRNA in alpha TC1 clone 6 cells
(Fig. S5). These lines of evidence suggest that TTR in pancreatic al-
pha cells may also be controlled by various transcription factors,
such as Pax6 and Foxa2, in response to hypoglycemia and may
serve as a mediator of up-regulation of glucagon expression. In
addition to the glucagon contents, because TTR is stored in secre-
tory vesicles [24], TTR may affect the secretion of glucagon. More-
over, since we also found that the expression levels of insulin was
also affected, but not obviously, by the lack of TTR (Fig. S2), further
investigation is needed to explain in detail the mechanism under-
lying cross-talk between glucagon and TTR expression in glucose
homeostasis. In addition, instead of normal cells, we used alpha
TC1 clone6 and PANC-1 cell lines to obtain supportive evidence
(Figs. 5 and 6). Unlike normal pancreatic alpha cells, alpha TC1
clone 6 cells express the high levels of glucagon by the control of
the rat preproglucagon promoter and terminally differentiated.
PANC-1 is an epithelioid carcinoma cell line derived from human
pancreas and secret the low levels of hormones. Our future studies
will focus on more precise determination by using the normal pan-
creatic alpha cells of the roles of TTR in glucose.
Other interesting ﬁndings of this study are that, different from
the situation in the liver, hypoglycemia that was induced by insulin
injections and fasting signiﬁcantly enhanced TTR expression in
pancreatic alpha cells, and starvation produced a similar result.
These ﬁndings suggest that TTR expression may be controlled by
speciﬁc transcriptional regulation in pancreatic alpha cells as de-
scribed above, which differ from hepatic cells. We will clarify the
mechanism in the future study.
In conclusion, unlike liver that synthesize TTR, the pancreas ex-
presses TTR by means of a distinct mechanism. In addition to thewell-known function of TTR, such as transporting thyroxine in
association with retinol-binding protein, TTR that is expressed in
pancreatic alpha cells may play important roles in glucose homeo-
stasis during glucose ﬂuctuations by regulating glucagon
expression.
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